Long-term follow-up results of a multi-institutional phase 2 study of concurrent chemoradiation therapy for locally advanced cervical cancer in east and southeast Asia.
OBJECTIVE
To report the long-term survival and toxicity of a multi-institutional phase 2 study of concurrent chemoradiation therapy (CCRT) for locally advanced cervical cancer in east and southeast Asia.


METHODS
Ten institutions from 8 Asian countries participated in the study. Between April 2003 and March 2006, 120 patients (60 with bulky stage IIB and 60 with stage IIIB) were treated with CCRT. Radiation therapy consisted of pelvic external beam radiation therapy and either high-dose-rate or low-dose-rate intracavitary brachytherapy. Five cycles of weekly cisplatin (40 mg/m(2)) were administered during the course of radiation therapy. Treatment results were evaluated by the rates of local control, overall survival, and late toxicities.


RESULTS
Median follow-up was 63.7 months, and the follow-up rate at 5 years was 98%. The 5-year local control and overall survival rates for all patients were 76.8% and 55.1%, respectively. The 5-year rates of major late toxicities of the rectum and bladder were 7.9% and 0%, respectively.


CONCLUSIONS
The long-term results have suggested that CCRT is safe and effective for patients with locally advanced cervical cancer in east and southeast Asia. However, further efforts are needed to improve overall survival.
Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan. s_kato@saitama-med.ac.jp
Shingo
S
Kato
Tatsuya
T
Ohno
Kullathorn
K
Thephamongkhol
Yaowalak
Y
Chansilpa
Jianping
J
Cao
Xiaoting
X
Xu
C R Beena
CR
Devi
Tang Tieng
TT
Swee
Miriam J C
MJ
Calaguas
Rey H
RH
de Los Reyes
Chul-Koo
CK
Cho
To Anh
TA
Dung
Nana
N
Supriana
Dyah
D
Erawati
Hideyuki
H
Mizuno
Takashi
T
Nakano
Hirohiko
H
Tsujii
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001210:Asia, Southeastern; D001918:Brachytherapy / Q000379:methods; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods*; D002681:China; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan; D008875:Middle Aged; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage; D012007:Rectum / Q000187:drug effects / Q000528:radiation effects; D056910:Republic of Korea; D015996:Survival Rate; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000187:drug effects / Q000528:radiation effects; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D002945:Cisplatin